A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China
Phase 1
Not yet recruiting
- Conditions
- Healthy Adult Subjects
- Interventions
- Drug: Rademikibart injectionDrug: CBP-201 injection
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 178
- Registration Number
- NCT06701149
SIM0718 Treatment of Asthma Clinical Study
Phase 3
Recruiting
- Conditions
- Asthma; Eosinophilic
- Interventions
- Drug: SIM0718 injection of placebo
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 418
- Registration Number
- NCT06488755
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis
Phase 3
Not yet recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: SIM0718 Injection
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 250
- Registration Number
- NCT06477835
Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients
Phase 2
Recruiting
- Conditions
- Post-stroke Cognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT06315231
- Locations
- 🇨🇳
Taihe County People's Hospital, Fuyang, Anhui, China
🇨🇳Hefei First People's Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS
Phase 3
Not yet recruiting
- Conditions
- Subjects With Acute Ischemic Stroke
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 880
- Registration Number
- NCT06176781
Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage
Phase 2
Recruiting
- Conditions
- Subjects With Cerebral Hemorrhage
- Interventions
- Drug: Synbixin/Placebo
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 380
- Registration Number
- NCT05953103
- Locations
- 🇨🇳
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Y-2 Sublingual TabletDrug: Placebo
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT05940883
- Locations
- 🇺🇸
Parexel International Los Angeles Early Phase Clinical Unit, Glendale, California, United States
Radiation Dose Study of Concurrent Chemoradiotherapy With Cisplatin Plus Fluorouracil in Oesophageal Cancer
Not Applicable
- Conditions
- Esophageal Neoplasms
- Interventions
- Radiation: Megavoltage photon beamDrug: cisplatin-fluorouracil chemotherapy
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 500
- Registration Number
- NCT01646853
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT01564329
- Locations
- 🇨🇳
The Department of Thoracic Oncology in West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT01317069
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath